Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. Despite good responses to standard of care frontline chemoimmunotherapy, the prognosis of relapsed/refractory (R/R) patients remains obscured by the possible inadequate responses to salvage therapy, eligibi...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Rita Assi, Nohad Masri, Iman Abou Dalle, Jean El-Cheikh, Hady Ghanem, Ali Bazarbachi
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	SAABRON PRESS 2021-03-01
Schriftenreihe:	Clinical Hematology International
Schlagworte:	DLBCL relapsed/refractory transplantation ADC polatuzumab vedotin
Online-Zugang:	https://www.atlantis-press.com/article/125953899/view
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!